...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics

With all the positive science data and publications that came out of the BETONMACE trial.  You would think RVX might just promote the hell of the data through the mass media venues from the help of the best  PR firms that could help get the message across to those that might want to move the SP. Where is the Canadian Biotech analyst coverage from any investment firm , ?If RVX want to move the SP up a lot how about hiring the appropriate investment banking firm to " look at the best strategic initiatives for shareholder value and put a Press release that they have hired a IB firm for help. We have heard partnership negotiations for years now . Was the debenture extension a negotiation tactic that RVX will wait for the best possible deal and won't settle until they get that. How are the day to day expenses being paid. shareholders need mores answers to those questions until then the SP won't be rising much IMO, it's getting very frustrating 

Share
New Message
Please login to post a reply